vs

Side-by-side financial comparison of Brookfield Infrastructure Corp (BIPC) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

Brookfield Infrastructure Corp is the larger business by last-quarter revenue ($866.0M vs $487.7M, roughly 1.8× CLOVER HEALTH INVESTMENTS, CORP.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — -10.1% vs -35.7%, a 25.6% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -4.6%).

Brookfield Infrastructure Partners L.P. is a publicly traded limited partnership with corporate headquarters in Toronto, Canada, that engages in the acquisition and management of infrastructure assets on a global basis.

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

BIPC vs CLOV — Head-to-Head

Bigger by revenue
BIPC
BIPC
1.8× larger
BIPC
$866.0M
$487.7M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+49.4% gap
CLOV
44.7%
-4.6%
BIPC
Higher net margin
CLOV
CLOV
25.6% more per $
CLOV
-10.1%
-35.7%
BIPC

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
BIPC
BIPC
CLOV
CLOV
Revenue
$866.0M
$487.7M
Net Profit
$-309.0M
$-49.3M
Gross Margin
65.0%
Operating Margin
62.7%
-10.1%
Net Margin
-35.7%
-10.1%
Revenue YoY
-4.6%
44.7%
Net Profit YoY
-148.1%
-123.2%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIPC
BIPC
CLOV
CLOV
Q4 25
$487.7M
Q3 25
$496.6M
Q2 25
$866.0M
$477.6M
Q1 25
$462.3M
Q4 24
$337.0M
Q3 24
$331.0M
Q2 24
$908.0M
$356.3M
Q1 24
$346.9M
Net Profit
BIPC
BIPC
CLOV
CLOV
Q4 25
$-49.3M
Q3 25
$-24.4M
Q2 25
$-309.0M
$-10.6M
Q1 25
$-1.3M
Q4 24
$-22.1M
Q3 24
$-9.2M
Q2 24
$643.0M
$7.4M
Q1 24
$-19.2M
Gross Margin
BIPC
BIPC
CLOV
CLOV
Q4 25
Q3 25
Q2 25
65.0%
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
63.8%
30.3%
Q1 24
23.6%
Operating Margin
BIPC
BIPC
CLOV
CLOV
Q4 25
-10.1%
Q3 25
-4.9%
Q2 25
62.7%
-2.2%
Q1 25
-0.3%
Q4 24
-6.4%
Q3 24
-2.7%
Q2 24
61.9%
2.0%
Q1 24
-6.5%
Net Margin
BIPC
BIPC
CLOV
CLOV
Q4 25
-10.1%
Q3 25
-4.9%
Q2 25
-35.7%
-2.2%
Q1 25
-0.3%
Q4 24
-6.6%
Q3 24
-2.8%
Q2 24
70.8%
2.1%
Q1 24
-5.5%

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIPC
BIPC
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$1.2B
$78.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.2B
$308.7M
Total Assets
$23.9B
$541.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIPC
BIPC
CLOV
CLOV
Q4 25
$78.3M
Q3 25
Q2 25
$1.2B
Q1 25
Q4 24
$194.5M
Q3 24
$288.0M
Q2 24
$466.0M
$254.8M
Q1 24
$208.3M
Stockholders' Equity
BIPC
BIPC
CLOV
CLOV
Q4 25
$308.7M
Q3 25
$340.9M
Q2 25
$2.2B
$344.2M
Q1 25
$336.1M
Q4 24
$341.1M
Q3 24
$342.2M
Q2 24
$3.5B
$324.9M
Q1 24
$292.5M
Total Assets
BIPC
BIPC
CLOV
CLOV
Q4 25
$541.0M
Q3 25
$559.7M
Q2 25
$23.9B
$575.0M
Q1 25
$583.7M
Q4 24
$580.7M
Q3 24
$653.0M
Q2 24
$23.7B
$674.2M
Q1 24
$671.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIPC
BIPC
CLOV
CLOV
Operating Cash FlowLast quarter
$478.0M
$-66.9M
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIPC
BIPC
CLOV
CLOV
Q4 25
$-66.9M
Q3 25
$12.1M
Q2 25
$478.0M
$5.4M
Q1 25
$-16.3M
Q4 24
$34.8M
Q3 24
$50.0M
Q2 24
$511.0M
$44.8M
Q1 24
$25.9M
Free Cash Flow
BIPC
BIPC
CLOV
CLOV
Q4 25
$-69.0M
Q3 25
$11.4M
Q2 25
$4.8M
Q1 25
$-16.5M
Q4 24
$33.3M
Q3 24
$49.6M
Q2 24
$44.4M
Q1 24
$25.5M
FCF Margin
BIPC
BIPC
CLOV
CLOV
Q4 25
-14.1%
Q3 25
2.3%
Q2 25
1.0%
Q1 25
-3.6%
Q4 24
9.9%
Q3 24
15.0%
Q2 24
12.5%
Q1 24
7.3%
Capex Intensity
BIPC
BIPC
CLOV
CLOV
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
BIPC
BIPC
CLOV
CLOV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.79×
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons